ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.074,02
-0,34%
S&P 500
5.300,32
1,02%
US Dollar vs BRL
5,1416
0,24%
Bitcoin
65.541,10
6,49%
Brent Oil
82,62
0,08%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Seagen Inc (SGEN)

  7. Seagen Inc (SGEN) Notícias

SGEN

Seagen (SGEN)

Seagen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SGEN
DataHoraFonteTítuloCódigoCompanhia
09/01/202408:12IH Market NewsWall Street Highlights: HPE and Juniper Networks in Negotiations, Elliott Invests $1 Billion in Match Group, and MoreNASDAQ:SGENSeagen Inc
26/12/202308:12Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:SGENSeagen Inc
18/12/202320:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGENSeagen Inc
18/12/202319:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SGENSeagen Inc
15/12/202319:00PR Newswire (US)PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder CancerNASDAQ:SGENSeagen Inc
14/12/202310:47Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGENSeagen Inc
14/12/202310:29Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:SGENSeagen Inc
14/12/202310:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGENSeagen Inc
14/12/202310:00Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:SGENSeagen Inc
12/12/202309:43Dow Jones NewsPfizer to Close $43 Billion Seagen Acquisition This WeekNASDAQ:SGENSeagen Inc
10/12/202321:30Business WireADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin LymphomaNASDAQ:SGENSeagen Inc
06/12/202310:15Business WireTUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast CancerNASDAQ:SGENSeagen Inc
30/11/202320:04Dow Jones NewsAstellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority ReviewNASDAQ:SGENSeagen Inc
30/11/202319:00Business WireFDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerNASDAQ:SGENSeagen Inc
13/11/202323:37Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:SGENSeagen Inc
13/11/202320:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SGENSeagen Inc
03/11/202313:00Business WireSeagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:SGENSeagen Inc
02/11/202314:00Business WireNew Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug ConjugateNASDAQ:SGENSeagen Inc
01/11/202309:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGENSeagen Inc
01/11/202309:00Business WireSeagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline ProgressNASDAQ:SGENSeagen Inc
22/10/202311:30Business WireTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 TrialNASDAQ:SGENSeagen Inc
22/10/202311:30Business WireGroundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder CancerNASDAQ:SGENSeagen Inc
20/10/202308:22IH Market NewsFriday’s Wall Street Highlights: SolarEdge, Intuitive Surgical, Knight-Swift, HPE, and moreNASDAQ:SGENSeagen Inc
16/10/202309:00Business WireSeagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023NASDAQ:SGENSeagen Inc
12/10/202309:00Business WireSeagen to Report Third Quarter 2023 Financial Results on November 1, 2023NASDAQ:SGENSeagen Inc
22/09/202308:02Dow Jones NewsMerck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits EndpointsNASDAQ:SGENSeagen Inc
22/09/202306:00Business WirePADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 TrialNASDAQ:SGENSeagen Inc
18/09/202308:25IH Market NewsMonday’s Wall Street Highlights: Cisco Systems, GM, Alibaba, SVB Financial, Clorox and MoreNASDAQ:SGENSeagen Inc
04/09/202316:00Business WireSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy AloneNASDAQ:SGENSeagen Inc
04/09/202316:00Business WireGenmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapyNASDAQ:SGENSeagen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SGEN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
LUPA3
LUPATECH ON
BOV
HAGA3
HAGA ON
BOV
PETR4
PETROBRAS PN
BOV
COGN3
COGNA ON
BOV
PRIO3
PETRORIO ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
AMAR3
LOJAS MARISA ON
BOV
ETER3
ETERNIT ON
BOV
HBOR3
HELBOR ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
GFSA3
GAFISA ON
BOV
AZEV3
AZEVEDO ON
BOV
GOLL4
GOL PN
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados